Coronay artery disase Gastroduodenal ulcer
Conditions
Interventions
Raveprazole (10 mg) will be given for 3 months in patinets who undergo PCI and take aspirin, after confirming the absence of endoscopic upper GI ulcer.
Placebo will be given for 3 months in patinets w
Sponsors
Nippon Medical School
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients with Coronary artery disease Patients who underwent Percutaneous coronary intervention using coronary stent Patinets who were treated with anti-platelets including aspirin
Exclusion criteria
Exclusion criteria: Patients having an episode of adverse effect by rabeprazole or other proton pump inhibitor Patients with severe liver or renal dysfunction Patients with NYHA III or IV heart failure Patients with pregnancy (including possible), or nursing patients Patients who are not judged to be appropreate by a study conductor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Gastroduodenal Ulcer or bleeding, Upper Gastrointestinal symptom and decrease in hemoglobin level 3 month after percutaneous coronary intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| Severity of gastroduodenal mucosal injury evaluated with LANZA score | — |
Countries
Japan
Contacts
Public ContactHitoshi Takano
Nippon Medical School Department of Medicine
Outcome results
None listed